Supplementary Table 1.
BMDD and OLS comparison of subgroups defined by clinical characteristics or treatment.
| BMDD-OUTCOMES | |||
|---|---|---|---|
| With insulin tx (n=13) | Without insulin tx (n=13) | p-value | |
| Cn.CaMean [wt%Ca] | 23.48 (0.66) | 23.16 (0.91) | 0.304 |
| Cn.CaPeak [wt%Ca] | 24.30 (0.58) | 23.98 (0.74) | 0.232 |
| Cn.CaWidth [Δwt%Ca] | 3.80 (0.36) | 3.95 (0.47) | 0.383 |
| Cn.CaLow [%B.Ar] | 4.33 (1.04) | 4.82 (1.75) | 0.397 |
| Cn.CaHigh [%B.Ar] | 5.03 (2.76; 7.65) | 3.06 (1.93; 6.71) | 0.305 |
| With CC (n=9) | Without CC (n=17) | p-value | |
| Cn.CaMean [wt%Ca] | 23.54 (0.51) | 23.20 (0.90) | 0.308 |
| Cn.CaPeak [wt%Ca] | 24.34 (0.43) | 24.04 (0.76) | 0.286 |
| Cn.CaWidth [Δwt%Ca] | 3.72 (0.37) | 3.96 (0.43) | 0.171 |
| Cn.CaLow [%B.Ar] | 4.04 (0.95) | 4.86 (1.59) | 0.171 |
| Cn.CaHigh [%B.Ar] | 5.59 (3.47; 7.42) | 3.06 (2.32; 7.39) | 0.388 |
| With fragility fx (n=3) | Without fragility fx (n=23) | p-value | |
| Cn.CaMean [wt%Ca] | 23.19 (0.68) | 23.34 (0.82) | 0.778 |
| Cn.CaPeak [wt%Ca] | 23.92 (0.46) | 24.17 (0.70) | 0.545 |
| Cn.CaWidth [Δwt%Ca] | 3.64 (0.17) | 3.90 (0.43) | 0.314 |
| Cn.CaLow [%B.Ar] | 3.43 (1.00) | 4.18 (1.18) | 0.310 |
| Cn.CaHigh [%B.Ar] | 17.60 (8.83) | 24.51 (12.78) | 0.377 |
| OLS-CHARACTERISTICS | |||
| HbA1c>7% (n=16) | HbA1c<7% (n=10) | p-value | |
| OLS-porosity (%) | 0.43 (0.09) | 0.43 (0.08) | 0.846 |
| OLS-density (nb./mm2) | 163.7 (17.5) | 168.0 (26.6) | 0.622 |
| OLS-area (µm2) | 26.3 (3.7) | 25.4 (3.0) | 0.530 |
| OLS-perimeter (µm) | 22.1 (1.6) | 21.9 (1.0) | 0.728 |
| OLS-AR | 2.8 (0.2) | 2.8 (0.2) | 0.419 |
| With insulin tx (n=13) | Without insulin tx (n=13) | p-value | |
| OLS-porosity (%) | 0.40 (0.06) | 0.39 (0.07) | 0.725 |
| OLS-density (nb./mm2) | 160.1 (15.3) | 164.0 (24.7) | 0.631 |
| OLS-area (µm2) | 24.9 (2.5) | 23.8 (2.3) | 0.244 |
| OLS-perimeter (µm) | 21.6 (1.1) | 21.4 (1.1) | 0.658 |
| OLS-AR | 2.7 (0.2) | 2.9 (0.2) | 0.069 |
| With CC (n=9) | Without CC (n=17) | p-value | |
| OLS-porosity (%) | 0.38 (0.05) | 0.40 (0.07) | 0.469 |
| OLS-density (nb./mm2) | 155.3 (11.0) | 165.6 (23.3) | 0.223 |
| OLS-area (µm2) | 24.5 (2.3) | 24.2 (2.5) | 0.784 |
| OLS-perimeter (µm) | 21.4 (1.1) | 21.5 (1.1) | 0.861 |
| OLS-AR | 2.7 (0.1) | 2.8 (0.2) | 0.307 |
| With fragility fx (n=3) | Without fragility fx (n=23) | p-value | |
| OLS-porosity (%) | 0.38 (0.04) | 0.40 (0.07) | 0.770 |
| OLS-density (nb./mm2) | 158.5 (14.7) | 162.5 (21.1) | 0.754 |
| OLS-area (µm2) | 24.2 (1.1) | 24.3 (2.5) | 0.956 |
| OLS-perimeter (µm) | 20.9 (0.4) | 21.5 (1.1) | 0.375 |
| OLS-AR | 2.63 (0.08) | 2.8 (0.2) | 0.093 |
Abbreviations: insulin tx=insulin treatment; CC=chronic complications including retinopathy and diabetic nephropathy; fragility fx=fragility fractures.
Data are mean (SD) and p-value from corresponding t-test or median (25th; 75th percentiles) and p-value from corresponding Mann-Whitney rank sum test (latter for non-normally distributed data). None of these comparisons is statistically different.